Chief Science Officer
PK Biosciences Corp.
1600 South 16 Street, 2087 Vet Med
Ames, IA 50011-1250
As a pharmacology faculty at the Univ. of Massachusetts Medical Center (1990-95) his major focus was to study the effect of ethanol and local anesthetics on Neuronal ligand-gated and ion-gated channels. Subsequently, he joined the research team headed by Dr. Alan J Tobin, Director of Brain Research Institute, UCLA (1995-97). His team focused on engineering immortalized neuronal cell lines to express GAD65 and produce GABA for transplantation experiments in animal models of Epilepsy, Parkinson’s and Huntington disease.
In his position as a senior scientist (1997-99), he was instrumental in developing high-throughput pharmacological screening and cellular response measuring instruments at Axiom Biotechnologies Inc. (merged with Sequenom Inc.). Since 2000, he is an affiliate Associate Professor in the Department of Biomedical Sciences in the College of Veterinary Medicine, Iowa State University. At ISU, Dr. Anantharam’s research focuses on areas of neurodegenerative diseases and neurotoxicology.
In 2006, he co-founded PK Bio. In 2008, he received NIH SBIR phase I funding for development of Novel Therapeutic Agents for Parkinson’s’ disease. In 2008, he also received the Iowa Technological Commercialization Fellowship Award. In 2009 he also received funding from Grow Iowa Value Fund and Institute for Physical Research and Technology from the State of Iowa for syntheses and screening of novel drugs for PD.